Henry Schein, Inc. (NASDAQ:HSIC) – Research analysts at Gabelli boosted their FY2020 EPS estimates for shares of Henry Schein in a research note issued on Monday. Gabelli analyst K. Kedra now anticipates that the company will post earnings per share of $5.00 for the year, up from their prior estimate of $4.98.
Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, August 8th. The company reported $0.88 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.86 by $0.02. Henry Schein had a net margin of 4.59% and a return on equity of 19.91%. The business had revenue of $3.06 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same period in the previous year, the business posted $0.82 earnings per share. The business’s revenue was up 6.4% compared to the same quarter last year. TRADEMARK VIOLATION NOTICE: This article was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.com-unik.info/2017/11/02/equities-analysts-offer-predictions-for-henry-schein-inc-s-fy2020-earnings-hsic.html.
A number of other analysts have also recently weighed in on the stock. Jefferies Group LLC reaffirmed a “hold” rating and issued a $89.00 price objective on shares of Henry Schein in a report on Friday, October 20th. Robert W. Baird set a $95.00 price objective on shares of Henry Schein and gave the stock a “buy” rating in a report on Thursday, October 19th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $89.00 price objective on shares of Henry Schein in a report on Thursday, October 19th. Morgan Stanley assumed coverage on shares of Henry Schein in a report on Thursday, September 21st. They issued an “equal weight” rating and a $88.00 price objective on the stock. Finally, Royal Bank Of Canada assumed coverage on shares of Henry Schein in a report on Tuesday, September 19th. They issued a “sector perform” rating and a $91.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $92.89.
Institutional investors and hedge funds have recently made changes to their positions in the business. Intrust Bank NA boosted its holdings in shares of Henry Schein by 1.1% in the second quarter. Intrust Bank NA now owns 1,219 shares of the company’s stock worth $223,000 after buying an additional 13 shares during the period. Bronfman E.L. Rothschild L.P. boosted its holdings in shares of Henry Schein by 4.0% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 14,859 shares of the company’s stock worth $2,719,000 after buying an additional 566 shares during the period. Bradley Foster & Sargent Inc. CT boosted its holdings in shares of Henry Schein by 2.1% in the second quarter. Bradley Foster & Sargent Inc. CT now owns 33,106 shares of the company’s stock worth $6,059,000 after buying an additional 690 shares during the period. Comerica Bank boosted its holdings in shares of Henry Schein by 10.6% in the second quarter. Comerica Bank now owns 21,833 shares of the company’s stock worth $4,054,000 after buying an additional 2,101 shares during the period. Finally, Aviva PLC boosted its holdings in shares of Henry Schein by 0.5% in the second quarter. Aviva PLC now owns 50,249 shares of the company’s stock worth $9,195,000 after buying an additional 230 shares during the period. Institutional investors own 47.48% of the company’s stock.
In other news, SVP Paul Rose sold 2,126 shares of Henry Schein stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $172.51, for a total value of $366,756.26. Following the transaction, the senior vice president now owns 17,841 shares of the company’s stock, valued at approximately $3,077,750.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.19% of the company’s stock.
Henry Schein announced that its board has approved a stock repurchase program on Monday, September 18th that authorizes the company to buyback $400.00 million in shares. This buyback authorization authorizes the company to repurchase up to 6.3% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its stock is undervalued.
About Henry Schein
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
What are top analysts saying about Henry Schein Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Henry Schein Inc. and related companies.